News | May 09, 2026
Lonza surges on biologics boom
Expands manufacturing push & locks in major growth deals
Expands manufacturing push & locks in major growth deals
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The private funding rose 38% amid growing international collaborations and CDMO demand
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
